Actively Recruiting
miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction
Led by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Updated on 2026-01-20
40
Participants Needed
1
Research Sites
37 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities. Current research has found that in the early stages of the disease, synaptic connections between brain nerve cells become abnormal, but the specific cause is still unclear. Investigators' previous research discovered that in the brains of diseased mice, certain special substances (the miR 342 5p/AnkG-mediated pathway) might be related to this abnormality, and these substances can be detected in both blood and cerebrospinal fluid. Therefore, investigators want to further explore the specific mechanisms of abnormal nerve cell connections, seek biomarkers for early detection of the disease, and provide new ideas for early diagnosis in the future.
CONDITIONS
Official Title
miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For Alzheimer's group: diagnosed with probable Alzheimer's dementia by NINCDS-ADRDA criteria
- MMSE score between 0 and 23 points
- Clinical Dementia Rating score of 0.5 or higher
- Hachinski Ischemic Score less than 4 points
- Brain MRI shows bilateral temporal lobe and hippocampal atrophy
- Age 50 years or older
- For control group: healthy individuals matched in age to Alzheimer's group
- Normal cognitive function and good daily living activities
- No dementia in first-degree relatives
- Negative brain MRI and neurological exam
You will not qualify if you...
- Dementia or cognitive impairment caused by other diseases
- History of substance abuse
- Progressive primary aphasia
- Previous traumatic brain injury
- Comorbid depression, schizophrenia, or severe cardiovascular, liver, kidney, or blood diseases
- Impaired consciousness or inability to cooperate
- Other conditions unsuitable for inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Yiwu, Zhejiang, China, 322000
Actively Recruiting
Research Team
X
Xu-hua Xu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here